Amantadine for the treatment of childhood and adolescent psychiatric symptoms

Morrow, Kyle; Choi, Seong Yeol; Young, Keith A.; Haidar, Makram; Boduch, Cassandra; Bourgeois, James A.

doi:10.1080/08998280.2021.1925827

Cited by 3 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As with amantadine, early studies showed promise, either as a monotherapy 157 or in combination with risperidone, 158 but the quality of the evidence is low. Based on a retrospective cohort study conducted at Baylor University in Texas between 2014 and 2018 on 297 children ages 6–18 years with psychiatric disorders (ADHD being the most common 251/297), amantadine (median dose 200 mg daily) resulted in favorable clinical outcomes in 67.8% (40/59) of individuals with ASD, suggesting its benefits in individuals with ADHD comorbid with ASD 159 …”

Section: Future Directionsmentioning

confidence: 99%

Off-label psychopharmacological interventions for autism spectrum disorders: strategic pathways for clinicians

Gupta¹,

Gupta²

2023

CNS Spectr.

View full text Add to dashboard Cite

The prevalence of autism spectrum disorder (ASD) continues to see a trend upward with a noticeable increase to 1 in 36 children less than 8 years of age in the recent MMWR. There are many factors linked to the substantially increased burden of seeking mental health services, and clinically these individuals are likely to present for impairments associated with co-occurring conditions. The advances in cutting-edge research and the understanding of co-occurring conditions in addition to psychosocial interventions have provided a window of opportunity for psychopharmacological interventions given the limited availability of therapeutics for core symptomatology. The off-label psychopharmacological treatments for these co-occurring conditions are central to clinical practice. However, the scattered evidence remains an impediment for practitioners to systematically utilize these options. The review collates the crucial scientific literature to provide stepwise treatment alternatives for individuals with ASD; with an aim to lead practitioners in making informed and shared decisions. There are many questions about the safety and tolerability of off-label medications; however, it is considered the best practice to utilize the available empirical data in providing psychoeducation for patients, families, and caregivers. The review also covers experimental medications and theoretical underpinnings to enhance further experimental studies. In summary, amidst the growing clinical needs for individuals with ASD and the lack of approved clinical treatments, the review addresses these gaps with a practical guide to appraise the risk and benefits of off-label medications.

show abstract

Section: Future Directionsmentioning

confidence: 99%

Off-label psychopharmacological interventions for autism spectrum disorders: strategic pathways for clinicians

Gupta¹,

Gupta²

2023

CNS Spectr.

View full text Add to dashboard Cite

show abstract

“…Один пациент в группе выбыл из исследования, и побочные эффекты были сопоставимы, за исключением снижения аппетита и беспокойства, которые имели более высокую частоту встречаемости при приеме метилфенидата. Эффективность обоих методов лечения была одинаковой в каждый момент времени с аналогичной тенденцией к снижению [50].…”

Section: препараты не зарегистрированные на территории рф по показани...unclassified

Attention Deficit Hyperactivity Disorder: Advanced Possibilities of Diagnostics and Therapy

Useinova,

Egorova,

Maryanenko

2023

Psychiatry

View full text Add to dashboard Cite

Background: attention deficit hyperactivity disorder (ADHD) is one of the urgent problems of psychoneurology. ADHD has a significant impact on the quality of life of a patient of any age. The variability of clinical manifestations depending on the age of the patient remain the subject of scientific discussion.The aim of the review: based on the scientific data of recent years, to study achievements in the field of diagnosis and rational choice of drugs used for the purpose of pharmacotherapy of patients of various age categories with ADHD.Materials and methods: the review is formed on the basis of scientific articles published in international databases (PubMed, Cochrane Library, Cyberleninka). The search was carried out using the following keywords: “attention deficit hyperreactivity syndrome”, “ADHD”, “psychostimulants”, “psychotropic drugs without psychoanaleptic effect”.Conclusion: the features of the development and evolution of ADHD over time, by the time the patient grows up, determine its clinical manifestations, they become more heterogeneous, which requires additional diagnostic efforts to clarify the diagnosis in order to select effective pharmacotherapy in combination with psychosocial methods of treatment. Currently, drugs with and without psychoanaleptic effect are used as drug therapy for ADHD. The most promising drugs for the treatment of ADHD are monoaminergic reuptake inhibitors, as well as drugs with melatonergic activity. Of considerable interest is the further study of drugs that affect the GABA system, glutamatergic and cannabinoid transmission in the brain. In general, the authors of analysed publications unanimously recognize that the problem of selecting effective therapy of ADHD in childs and adult patients requires further study and the proposal of new means of correction.

show abstract

Drugs with glutamate-based mechanisms of action in psychiatry

Chrobak,

Siwek

2024

Pharmacol. Rep

View full text Add to dashboard Cite

Psychopharmacotherapy of major psychiatric disorders is mostly based on drugs that modulate serotonergic, dopaminergic, or noradrenergic neurotransmission, either by inhibiting their reuptake or by acting as agonists or antagonists on specific monoamine receptors. The effectiveness of this approach is limited by a significant delay in the therapeutic mechanism and self-perpetuating growth of treatment resistance with a consecutive number of ineffective trials. A growing number of studies suggest that drugs targeting glutamate receptors offer an opportunity for rapid therapeutic effect that may overcome the limitations of monoaminergic drugs. In this article, we present a review of glutamate-modulating drugs, their mechanism of action, as well as preclinical and clinical studies of their efficacy in treating mental disorders. Observations of the rapid, robust, and long-lasting effects of ketamine and ketamine encourages further research on drugs targeting glutamatergic transmission. A growing number of studies support the use of memantine and minocycline in major depressive disorder and schizophrenia. Amantadine, zinc, and Crocus sativus extracts yield the potential to ameliorate depressive symptoms in patients with affective disorders. Drugs with mechanisms of action based on glutamate constitute a promising pharmacological group in the treatment of mental disorders that do not respond to standard methods of therapy. However, further research is needed on their efficacy, safety, dosage, interactions, and side effects, to determine their optimal clinical use.

show abstract

Amantadine for the treatment of childhood and adolescent psychiatric symptoms

Cited by 3 publications

References 27 publications

Off-label psychopharmacological interventions for autism spectrum disorders: strategic pathways for clinicians

Off-label psychopharmacological interventions for autism spectrum disorders: strategic pathways for clinicians

Attention Deficit Hyperactivity Disorder: Advanced Possibilities of Diagnostics and Therapy

Drugs with glutamate-based mechanisms of action in psychiatry

Contact Info

Product

Resources

About